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Objective: We recently observed a greater increase in plasma levels of bioactive
glucose-dependent insulinotropic polypeptide (GIP) than glucagon-like peptide 1 (GLP-1)
using the receptor-mediated bioassays in the subjects with normal glycemic tolerance
(NGT) treated with dipeptidyl peptidase 4 (DPP-4) inhibitors, whichmay be unappreciated
using conventional enzyme-linked immunosorbent assays (ELISAs) during oral glucose
tolerance test. Thus, we determined incretin levels in addition to glucagon level using
the bioassays in type 2 diabetes mellitus (T2DM) subjects with or without treatment of
DPP-4 inhibitor, to evaluate whether these assays can accurately measure bioactivity of
these peptides.
Methods: We performed single meal tolerance test (MTT) by using a cookie meal
(carbohydrate 75.0 g, protein 8.0 g, fat 28.5 g) in the subjects with NGT (n = 9), the
subjects with T2DM treated without DPP-4 inhibitor (n = 7) and the subjects with T2DM
treated with DPP-4 inhibitor (n = 10). All subjects fasted for 10–12 h before the MTT,
and blood samples were collected at 0, 30, 60, and 120min. We used the cell lines
stably cotransfected with human-form GIP, GLP-1 or glucagon receptor, and a cyclic
adenosine monophosphate–inducible luciferase expression construct for the bioassays.
We measured active GIP, active GLP-1, and glucagon by the bioassays. To evaluate the
efficacy of bioassay, we measured identical samples via ELISA kits.
Results: During the single MTT study, postprandial active GIP bioassay levels
of T2DM with DPP-4 inhibitor treatment were drastically higher than those of
NGT and T2DM without DPP-4 inhibitor, although the DPP-4 inhibitor-treated
group showed moderate increase of active GIPELISA and active GLP-1bioassay,
while active GLP-1bioassay levels of T2DM subjects without DPP-4 inhibitor were
comparable to those of NGT subjects. During the serial MTT, administration of DPP-4
inhibitor significantly increased active GIPbioassay levels, but not active GLP-1bioassay.
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Conclusions: In comparison to conventional ELISA, receptor-mediated bioassay
reflects dynamic change of GIP polypeptide by DPP-4 inhibitor treatment in subjects
with type 2 diabetes.
Keywords: glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, glucagon, receptor-mediated
bioassay, dipeptidyl peptidase 4
INTRODUCTION
Glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide 1 (GLP-1) are incretin hormones, released
from the intestine by oral ingestion of various nutrients (1, 2).
They stimulate insulin secretion from beta cells in the islet (1, 2)
and are cleaved rapidly after secretion by dipeptidyl peptidase
4 (DPP-4) (3). Pro-GIP and proglucagon are processed to
GIP and GLP-1 in the gut by prohormone convertase (PC)
1/3, respectively (4–6). Glucose-dependent insulinotropic
polypeptide consists of 42 amino acids and is secreted from
K-cells in the upper small intestine (1, 2, 6).
Interestingly, it is reported that pro-GIP is processed to
a short-form GIP (1–30)NH2 in the pancreatic alpha cells
and the gastrointestinal tract by PC2 (5, 7), and this form
has insulinotropic activity almost equivalent to GIP(1–42) (7).
Further, proglucagon is alternatively modified to GLP-1 in the
pancreatic alpha cells during some metabolic states by PC1/3 (8).
Recently, several enzyme-linked immunosorbent assay
(ELISA) kits have been developed to measure specifically active
GIP and GLP-1, but it is unclear if these kits can accurately
quantify all bioactive forms. Indeed, short-form GIP(1–30)NH2
could never be detected by total and active GIP ELISA kits;
however, we confirmed that it increased receptor-mediated
cyclic adenosine monophosphate (cAMP) production in a
concentration-dependent manner in our cell-based receptor-
mediated bioassay (9). Additionally, we reported that plasma
active GIP bioassay levels were boosted by DPP-4 inhibitor
administrated in non-diabetic subjects during oral glucose
tolerance test (OGTT), whereas total GIPELISA and active
GIPELISA levels indicated only mild increases (9). Therefore,
commercial ELISA kits may underestimate incretin activities
particularly GIP under DPP-4 inhibitor treatment.
In the current study, we here determined active GIP, GLP-1,
and glucagon levels in type 2 diabetes mellitus (T2DM) subjects
with or without DPP-4 inhibitor treatment to characterize
the cell-based, receptor-mediated bioassays in comparison
to immunoassays.
MATERIALS AND METHODS
Subjects and Study Protocol
We recruited Japanese subjects with normal glucose tolerance
(NGT: n = 9) and T2DM subjects [without DPP-4 inhibitor
Abbreviations: BMI, body mass index; CRE-Luc, cyclic AMP-inducible luciferase;
DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; GIP,
glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1;
KRB, Krebs Ringer Buffer; MTT, meal tolelance test; NGT, normal glycemic
control; OGTT, oral glucose tolerance test; PC, prohormone convertase; T2DM,
type 2 diabetes.
treatment: n = 7, with DPP-4 inhibitor treatment: n = 10
(sitagliptin: n = 6, vildagliptin: n = 2, anagliptin: n = 1,
alogliptin: n = 1)]. The written informed consent was obtained
from all participants. The study was performed in accordance
with the Declaration of Helsinki, and the research protocol
was approved by the Research Ethics Committee of Asahikawa
Medical University (approved protocol no. 1074-2). The clinical
characteristics of the subjects are shown in Table 1.
We performed single meal tolerance test (MTT) by using a
cookie meal (Meal test CTM; Saraya Corporation, Osaka, Japan;
592 kcal, carbohydrate 75.0 g, protein 8.0 g, fat 28.5 g) from 2014
to 2017 (10–12). All subjects were fasted for 10–12 h before the
MTT. We collected blood samples at 0, 30, 60, and 120min using
blood collection tubes containing DPP-4 inhibitor (P800; BD,
Tokyo, Japan).
We excluded subjects with type 1 diabetes, malignancy,
renal failure, pregnancy, other endocrine disorders, and
steroid medication.
The plasma samples were separated by centrifugation (3,000
revolutions/min, 15min, 4◦C) and then stored at −80◦C
until assays.
Assays
Plasma GIP, GLP-1, and glucagon levels were measured
by ELISA and our bioassays employing HEK293 cell lines
TABLE 1 | Participants characteristics.
NGT T2DM
DPP-4 inhibitor (–) DPP-4 inhibitor (+)





Insulin — 4 2
Sulfonylurea — — 1
Metformin — 2 8
Pioglitazone — 1 1
Age (year) 65.4 ± 4.5 66.6 ± 3.6 65.8 ± 3.2
BMI (kg/m2) 26.1 ± 1.5 25.0 ± 1.0 27.0 ± 1.3
eGFR (mL/min per
1.73 m2 )
69.5 ± 3.3 80.9 ± 9.2 63.9 ± 5.4
HbA1c (%) 5.7 ± 0.1 8.6 ± 0.9 6.7 ± 0.2
Date are presented as means ± SEM. Age, BMI, eGFR: 1-way ANOVA by the Tukey
post hoc test. HbA1c, Mann–Whitney U test [DPP-4 inhibitor (–) vs. DPP-4 inhibitor
(+)].BMI, body mass index; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular
filtration rate; HbA1c, hemoglobin A1c; NGT, normal glycemic control; T2DM, type
2 diabetes.
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stably cotransfected with human forms of the GIP receptor,
GLP-1 receptor, or glucagon receptor (GCGR), respectively,
and a cAMP-inducible luciferase (CRE-Luc) expression
construct (9). For ELISAs, we used total GIP (EZHGIP-
54K; Millipore, Tokyo, Japan), active GIP (#27201; IBL,
Fujioka, Japan), total GLP-1 (EZGLP1T-36K; Millipore),
and glucagon (#10-1281-01; Mercodia, Uppsala, Sweden).
Each assay was performed with previously unthawed
plasma samples.
For the bioassays, we utilized HEK293 cell lines stably
cotransfected with human-form GIP, GLP-1, or glucagon
receptor and a CRE-Luc expression construct. The cell lines were
cultured in DMEM (25 mmol/L glucose) with 10% (vol/vol)
fetal bovine serum (FBS) (MP Biomedicals, Santa Ana, CA,
USA), 100 IU/mL penicillin, and 100µg/mL streptomycin
(Invitrogen, Tokyo, Japan) at 37◦C in 5% CO2. Cells were
harvested overnight on 96-well plates (100,000 cells/well). Media
was then replaced with samples or various concentrations of
synthetic peptides [GIP bioassay: GIP(1–42), GIP(1–30)NH2,
GLP-1(7–36)NH2, glucagon(1–29) and oxyntomodulin; 10
−13–
10−7 mol/L, GLP-1 bioassay: GLP-1(7–36)NH2, GIP(1–42),
GIP(1–30)NH2, glucagon(1–29), and oxyntomodulin; 10
−13–
10−9 mol/L, glucagon bioassay: glucagon(1–29), oxyntomodulin,
GIP(1–42), GIP(1–30)NH2 and GLP-1(7–36)NH2; 10
−13–10−9
mol/L] that were diluted in Krebs–Ringer buffer (KRB) (pH
7.4) containing 0.5% (wt/vol) bovine serum albumin (Sigma-
Aldrich, Tokyo, Japan) and incubated for 5 h at 37◦C in 5%
CO2. We diluted plasma samples with KRB before active
GIP, active GLP-1, and glucagon measurement by bioassay
(GIP: 20-fold dilution, GLP-1: 50-fold dilution, glucagon:
20-fold dilution). After incubation, we measured luciferase
activity with the Bright-Glo Assay Kit (Promega, Madison,
WI, USA) using Thermo Scientific Appliskan (Thermo Fisher
Scientific, Waltham, MA, USA) according to the manufacturer’s
instructions and calculated the hormone concentrations as
previously described (9).
Peptides and Enzyme
GIP(1–42), GLP-1(7–36)NH2, and glucagon(1–29) were
purchased from Peptide Institute (Osaka, Japan). Glucose-
dependent insulinotropic polypeptide(1–30)NH2 was purchased
from Phoenix Pharmaceuticals (Burlingame, CA, USA).
Oxyntomodulin was purchased from American Peptide
(Sunnyvale, CA, USA). Dipeptidyl peptidase 4 inhibitor was
purchased fromMillipore.
Statistical Analysis
Data are expressed as mean ± SEM. Statistical analysis
was performed by Mann–Whitney U test, one-
way analysis of variance (ANOVA) (followed by the
Tukey post hoc test or two-way repeated ANOVA
followed by the Bonferroni post hoc test. Data were
analyzed using the commercial software (Prism 5;
GraphPad, San Diego, CA, USA), and p < 0.05 was
considered significant.
RESULTS
The Receptor-Mediated Bioassay and
ELISA
To evaluate the specificity and the characteristics of the
bioassays, we examined their responsiveness with several
synthetic glucagon-related peptides. In the GIP bioassay, GIP(1–
42) and GIP(1–30)NH2 almost equivalently increased luciferase
activity in a concentration-dependent manner. Glucagon-like
peptide 1(7–36)NH2, glucagon, and oxyntomodulin did not
increase luciferase activity at any concentration (Figure 1A).
In the GLP-1 bioassay, GLP-1(7–36)NH2 increased luciferase
activity in a concentration-dependent manner. Glucagon and
oxyntomodulin induced luciferase activity at concentrations >
∼10−11 and 3 × 10−12 mol/L, respectively (Figure 1B). In
the glucagon bioassay, glucagon and oxyntomodulin increased
luciferase activity in a concentration-dependent manner, and
they showed almost the equivalent bioactivities. Glucose-
dependent insulinotropic polypeptide induced luciferase activity
at concentrations > ∼10−8 mol/L (Figure 1C).
Neither total nor active GIP ELISA kits detected GIP(1–
30)NH2 as we previously reported (9). Glucagon ELISA kit did not
detect GIP(1–42) and GIP(1–30)NH2. The cross-reactivity against
oxyntomodulin (measurement range, 1–500 pmol/L) was ∼5%
(Supplementary Figure 1).
High Active GIP Levels by Bioassay in
T2DM Subjects Under DPP-4 Inhibitor
Treatment
During MTT study, fasting and postprandial total GIP ELISA
levels in T2DM subjects with DPP-4 inhibitor treatment
were comparable to NGT, but the postprandial levels of
T2DM subjects without DPP-4 inhibitor tended to be lower
than those of T2DM subjects with DPP-4 inhibitor, but not
significantly (Figure 2A). Postprandial active GIP bioassay and
active GIPELISA levels in T2DM subjects with DPP-4 inhibitor
were significantly higher than those in T2DM without DPP-
4 inhibitor (Figures 2B,C). In contrast, postprandial active
GIP bioassay level in T2DM subjects without DPP-4 inhibitor
tended to be lower than those in NGT, as well as total GIP
ELISA and active GIP ELISA levels (Figures 2A–C). Postprandial
active GLP-1 bioassay and total GLP-1ELISA levels in T2DM with
DPP-4 inhibitor were significantly higher than those of T2DM
without DPP-4 inhibitor and NGT (Figures 2D,E). Fasting
and postprandial active GLP-1 bioassay levels of T2DM subjects
without DPP-4 inhibitor were comparable to those of NGT
subjects (Figures 2D,E).
Among the T2DM subjects with DPP-4 inhibitor treatment,
active GIP bioassay levels were increased ∼15-fold at 30min
compared to without DPP-4 inhibitor (Figure 2C). In contrast,
total GIPELISA and active GIPELISA at 30min were only 2- and
2.5-fold greater than that of T2DM without DPP-4 inhibitor,
respectively (Figures 2A,B). Moreover, active GLP-1 bioassay did
not show such large changes as in GIP via the administration of
DPP-4 inhibitor. Total GLP-1ELISA and active GLP-1 bioassay levels
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A B C
FIGURE 1 | The receptor-mediated bioassay. The responsiveness and specificity of (A) GIP, (B) GLP-1, and (C) glucagon receptor-mediated bioassays with GIP,
GLP-1, glucagon, and oxyntomodulin peptides. White circle, GIP(1–42); black circle, GIP(1–30)NH2; white square, GLP−1(7-36)NH2; black square, glucagon; white




FIGURE 2 | Plasma GIP and GLP-1 levels of NGT and T2DM subjects during the MTT. We performed single MTT by using a cookie meal and measured plasma total
GIP (A), active GIP (ELISA) (B), active GIP (bioassay) (C), total GLP-1 (D), and active GLP-1 (bioassay) (E). White circle, NGT; white square, T2DM without DPP-4
inhibitor; black square, T2DM with DPP-4 inhibitor. Data are presented as means ± SEM. #$p < 0.05, ##$$p < 0.01, ###$$$p < 0.001, ####$$$$p < 0.0001.
# indicates NGT vs. DPP-4 inhibitor (+), $ is DPP-4 inhibitor (–) vs. DPP-4 inhibitor (+).DPP-4, dipeptidyl peptidase-4; GIP, glucose-dependent insulinotropic
polypeptide; GLP-1, glucagon-like peptide 1; NGT, normal glycemic control; T2DM, type 2 diabetes.
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at 30min were only 2.6- and 5.3-fold greater than that of T2DM
without DPP-4 inhibitor treatment, respectively (Figures 2D,E).
Glucagon levels tended to increase after MTT in T2DM
subjects. Glucagon bioassay, but not glucagon ELISA, levels
in T2DM showed significantly higher than those of NGT
(Supplementary Figures 2A,B).
DISCUSSION
In clinical settings, plasma GIP and GLP-1 are conventionally
measured by ELISA. These ELISA kits have been developed
to measure specifically total/active GIP or GLP-1. However,
these kits might be expected with difficulty to distinguish
similar amino-acid sequence or multiple isoforms.We previously
showed that some GIP commercial ELISA kits could not detect
short-form GIP(1–30)NH2 (9). Therefore, all active forms may
not be evaluated by immunological assays. Additionally, we
confirmed that oxyntomodulin can stimulate GLP-1 based on our
receptor-mediated bioassay. In physiological aspects, we propose
that receptor-mediated bioassays are beneficial to reflect actions
of each peptide and can explain the gaps between hormone
action and plasma levels measured by ELISA. It is apparently
important to measure concentration of peptides such as glucagon
and glucagon-related peptides, specifically, and respectively.
However, it is also crucial in physiological aspects to measure
accurate bioactivity of glucagon-receptor activation, because it is
reported that oxyntomodulin also stimulates glucagon receptor,
as well as GLP-1 receptor. Indeed, our bioassay can detect
glucagon-receptor activation by oxyntomodulin. Therefore, our
bioassay is more useful than conventional ELISA in respect of
assessing bioactivity.
In our current MMT study, T2DM subjects with DPP-4
inhibitor treatment presented significantly elevated postprandial
active GIP bioassay than those of T2DM without the treatment,
similarly to our previous study examined in NGT subjects
(9). Active GIPELISA and total GIPELISA levels also were
increased, but those increments were smaller than that in
active GIP bioassay under the DPP-4 inhibitor treatment. Glucose-
dependent insulinotropic polypeptide(1–42) is secreted from
the gut K cells and processed from pro-GIP by PC1/3 (4, 5).
Additionally, pro-GIP is processed to, another GIP isoform,
short-form GIP(1–30)NH2 in the pancreatic alpha cells and in
the gut by PC2 (7). On the other hand, GIP(1–42) and GIP(1–
30)NH2 are almost equivalently cleaved by DPP-4 in a few
minutes after secretions. We presume that the receptor-mediated
bioassay can reflect to dynamic change of active GIP by DPP-
4 inhibitor, because the bioassay, but not ELISA, was able to
detect both GIP(1–42) and GIP(1–30)NH2. Therefore, it can be
great advantage to measure GIP by our bioassay, instead of
conventional ELISA kits.
Glucagon-like peptide 1 also has two active forms, GLP-
1(7–36)NH2 and GLP-1(7–37). Here, active GLP-1 bioassay was
slightly enhanced by DPP-4 inhibitor, which was comparably
assessed by the bioassay or ELISA. Collectively, DPP-4 inhibitor
might contribute to enhancing bioactive GIP more extensively
than GLP-1.
The present study demonstrated that GIP and GLP-1 in
T2DM without DPP-4 inhibitor were lower than those of
NGT, although previous reports indicated that plasma GIP
and GLP-1 levels in subjects with T2DM are increased,
comparable, or decreased compared to those in NGT subjects
based on ELISA assays (13, 14). The previous reports were
variable because those studies were performed occasionally
with OGTT or MTT. In fact, the differences of nutrients
can differently affect GIP and GLP-1 secretions. Glucose-
dependent insulinotropic polypeptide and GLP-1 secretions are
stimulated by glucose (15, 16). Additionally, other nutrients
such as fat and amino acids also promote incretin secretions
(16). Especially GIP secretion is strongly enhanced by fat (17,
18). In the current study, we performed MTT by using the
cookie meal. Unlike OGTT, the cookie meal is composed of
carbohydrate, protein, and fat. Other MTT study also used test
meal composed of various nutrients (19, 20). Therefore, we
presume that GIP/GLP-1 secretion is inconsistent during OGTT
or MTT.
There are several limitations in this study. First, our results
were based on a small number of subjects. Second, characteristics
of the subjects were relatively diverse. Therefore, big cohort
studies with sufficient number of subjects are necessary to
be examined for further understandings. Additionally, our
bioassays can detect all agonist to the receptors, and we
estimated bioactivities only through PKA-cAMP activities
signaling pathways. However, other pathways besides PKA-
cAMP pathway might be involved in signaling after receptor
biding, contributing physiological actions. Thus, it is still unclear
whether luciferase activities in receptor-mediated bioassay
represent all actions in vivo. Finally, Miyachi et al. presented
the quantitative method for GIP using Liquid Chromatography-
Triple Mass Spectrometry (LC-MS/MS/MS) (21). The technique
may be able to detect both GIP(1–42) and GIP(1–30)NH2.
LC-MS/MS/MS could provide us more outcomes in addition
to our results. In addition, we are now developing new GIP
ELISA system specifically to assess GIP(1–30)NH2 concentration.
We expect further consequences can be obtained through our
new system.
In conclusion, total and active GIP ELISA kits did not reflect
all bioactive GIP increased by DPP-4 inhibitor treatment. In
comparison to conventional ELISA, receptor-mediated bioassay
reflects dynamic change of GIP by DPP-4 inhibitor treatment in
subjects with type 2 diabetes.
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